a
d

WE ARE BRUNN

Let’s Work Together

FHL CB-101

Scientific Background +

FHL CB-101 is derived from natural ingredients and an FDA-approved food additive which is generally regarded as a safe substance. It is cleaved by lipases to produce NaB in the body, resulting in therapeutically beneficial slow-release and high-exposure drug delivery. While NaB, when taken directly, is rapidly excreted through urine and therefore high doses are often required to be efficacious, a steady and amplified level of NaB in the blood with a lower dose significantly minimizes side effects associated with high doses of NaB.

 

This disease-modifying treatment is under development for Parkinson’s Disease (PD) and Alzheimer’s Disease (AD), including a patient-friendly drug formulation.

 

Currently, no drugs are available to treat and cure PD and the patients rely on symptomatic drugs only. PD primarily affects neurons in an area of the brain known as substantia nigra and results in the loss of neurons that produce dopamine, neurotransmitters that relay messages between substantia nigra and other parts of the brain to control muscle movements.

 

FHL CB-101 has shown very promising efficacies to treat the progression of PD in both mouse and monkey animal models with minimal side effects. FHL CB-101 is believed to have a number of the mechanism of action which promotes dopaminergic activities in the striatum, attenuates inflammation and also upregulates neurotropic factors. In addition, hemiparkinsonian monkeys treated with FHL CB-101 have shown improvement in constipation.

Fig 1: Substantia Nigra
Fig 2: Reduced Dopamine-level

Murine Model for Parkinson’s Disease +

FHL CB-101 treatment increased level of DJ-1 expression and dopaminergic neuron density in substantia nigra of PD model mice (MPTP1-intoxicated mice).

Figure A visually shows upregulation of dopamine in  nigrostriatum in MPTP-intoxicated mice by FHL CB-101.
Figure B shows how FHL CB-101 protects and increases the level of TH and DJ-1 in the nigra of MPTP-intoxicated mice.
Figure C also shows how FHL CB-101 protects dopamine in the striatum of MPTP-intoxicated mice.

Hemiparkinsonian Monkey Model +

CB-101 (GTB) treatment protected nigral dopaminergic neurons in hemiparkinsonian monkeys.